U.S. FDA Noticed Data Tampering At Ipca’s Ratlam Unit, Expert Says
This article was originally published in PharmAsia News
Executive Summary
Ipca, the mid-sized emerging Indian drug maker, had staffers who allegedly overwrote raw data and adjusted systems to achieve passing GMP results, says an expert claiming access to the specific FDA observations.